These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 32088207

  • 1. A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S).
    Gelfand JM, Shin DB, Duffin KC, Armstrong AW, Blauvelt A, Tyring SK, Menter A, Gottlieb S, Lockshin BN, Simpson EL, Kianifard F, Sarkar RP, Muscianisi E, Steadman J, Ahlman MA, Playford MP, Joshi AA, Dey AK, Werner TJ, Alavi A, Mehta NN.
    J Invest Dermatol; 2020 Sep; 140(9):1784-1793.e2. PubMed ID: 32088207
    [Abstract] [Full Text] [Related]

  • 2. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.
    Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, Parneix A, Regnault P, You R, Milutinovic M.
    Br J Dermatol; 2019 Nov; 181(5):954-966. PubMed ID: 30367462
    [Abstract] [Full Text] [Related]

  • 3. Bimekizumab versus Secukinumab in Plaque Psoriasis.
    Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, De Cuyper D, Vanvoorden V, Madden C, Cioffi C, Peterson L, Blauvelt A.
    N Engl J Med; 2021 Jul 08; 385(2):142-152. PubMed ID: 33891380
    [Abstract] [Full Text] [Related]

  • 4. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA, Weinberg MA, Morris A, Reich K.
    Lancet; 2021 Apr 24; 397(10284):1564-1575. PubMed ID: 33894834
    [Abstract] [Full Text] [Related]

  • 5. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A.
    J Am Acad Dermatol; 2018 Aug 24; 79(2):277-286.e10. PubMed ID: 29609013
    [Abstract] [Full Text] [Related]

  • 6. Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.
    Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, Fuxench ZC, Harrington CL, Hubbard RA, Kalb RE, Menter A, Rader DJ, Reilly MP, Simpson EL, Takeshita J, Torigian DA, Werner TJ, Troxel AB, Tyring SK, Vanderbeek SB, Van Voorhees AS, Playford MP, Ahlman MA, Alavi A, Gelfand JM.
    Circ Cardiovasc Imaging; 2018 Jun 24; 11(6):e007394. PubMed ID: 29776990
    [Abstract] [Full Text] [Related]

  • 7. Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks.
    von Stebut E, Reich K, Thaçi D, Koenig W, Pinter A, Körber A, Rassaf T, Waisman A, Mani V, Yates D, Frueh J, Sieder C, Melzer N, Mehta NN, Gori T.
    J Invest Dermatol; 2019 May 24; 139(5):1054-1062. PubMed ID: 30508547
    [Abstract] [Full Text] [Related]

  • 8. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
    Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H, ERASURE Study Japanese subgroup.
    J Dermatol; 2014 Dec 24; 41(12):1039-46. PubMed ID: 25354738
    [Abstract] [Full Text] [Related]

  • 9. Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab.
    Morita A, Tani Y, Matsumoto K, Yamaguchi M, Teshima R, Ohtsuki M.
    J Dermatol; 2020 May 24; 47(5):452-457. PubMed ID: 32173900
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
    Papp K, Warren RB, Green L, Reich K, Langley RG, Paul C, Asahina A, Johnson L, Arora V, Osuntokun O, Lebwohl M.
    Lancet Rheumatol; 2023 Sep 24; 5(9):e542-e552. PubMed ID: 38251498
    [Abstract] [Full Text] [Related]

  • 11. Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab.
    Tomalin LE, Kolbinger F, Suprun M, Wharton KA, Hartmann N, Peters T, Glueck A, Milutinovic M, Krueger JG, Suárez-Fariñas M.
    Clin Exp Dermatol; 2024 Jul 19; 49(8):801-809. PubMed ID: 38240024
    [Abstract] [Full Text] [Related]

  • 12. Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial.
    Gelfand JM, Shin DB, Armstrong AW, Tyring SK, Blauvelt A, Gottlieb S, Lockshin BN, Kalb RE, Fitzsimmons R, Rodante J, Parel P, Manyak GA, Mendelsohn L, Noe MH, Papadopoulos M, Syed MN, Werner TJ, Wan J, Playford MP, Alavi A, Mehta NN.
    JAMA Dermatol; 2022 Dec 01; 158(12):1394-1403. PubMed ID: 36129688
    [Abstract] [Full Text] [Related]

  • 13. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
    Krueger JG, Wharton KA, Schlitt T, Suprun M, Torene RI, Jiang X, Wang CQ, Fuentes-Duculan J, Hartmann N, Peters T, Koroleva I, Hillenbrand R, Letzkus M, Yu X, Li Y, Glueck A, Hasselberg A, Flannery B, Suárez-Fariñas M, Hueber W.
    J Allergy Clin Immunol; 2019 Sep 01; 144(3):750-763. PubMed ID: 31129129
    [Abstract] [Full Text] [Related]

  • 14. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
    Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D.
    Br J Dermatol; 2022 Jun 01; 186(6):942-954. PubMed ID: 34981829
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
    Papp KA, Gooderham M, Lynde C, Brassard D, Al-Mohammedi F, Prajapati VH, Delorme I, Albrecht L, Haydey R, Alam MS, Beecker J, Siddha S, Maguin M, Farag MS, Vieira A, Rihakova L, Langley RG.
    Arch Dermatol Res; 2024 Jun 08; 316(7):362. PubMed ID: 38850346
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study.
    Wu NL, Hsu CJ, Sun FJ, Tsai TF.
    J Dermatol; 2017 Oct 08; 44(10):1129-1137. PubMed ID: 28493369
    [Abstract] [Full Text] [Related]

  • 17. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A.
    Lancet; 2019 Sep 07; 394(10201):831-839. PubMed ID: 31402114
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
    McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma S, Schumacher MM, Bertolino AP, Hueber W, Tak PP.
    Ann Rheum Dis; 2014 Feb 07; 73(2):349-56. PubMed ID: 23361084
    [Abstract] [Full Text] [Related]

  • 19. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, ERASURE Study Group, FIXTURE Study Group.
    N Engl J Med; 2014 Jul 24; 371(4):326-38. PubMed ID: 25007392
    [Abstract] [Full Text] [Related]

  • 20. 18F-fluorodeoxyglucose positron emission tomography-based evaluation of systemic and vascular inflammation and assessment of the effect of systemic treatment on inflammation in patients with moderate-to-severe psoriasis: A randomized placebo-controlled pilot study.
    Kaur S, Shafiq N, Dogra S, Mittal BR, Attri SV, Bahl A, Narang T, Vinay K, Rajagopalan S, Malhotra S.
    Indian J Dermatol Venereol Leprol; 2018 Jul 24; 84(6):660-666. PubMed ID: 29893297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.